Advertisement

Pathology & Oncology Research

, Volume 23, Issue 2, pp 385–392 | Cite as

Relationships between Common and Novel Interleukin-6 Gene Polymorphisms and Risk of Cervical Cancer: a Case-Control Study

  • Sabrina ZidiEmail author
  • Mouna Stayoussef
  • Bano L. Alsaleh
  • Ezzedine Gazouani
  • Amel Mezlini
  • Bashayer H. Ebrahim
  • Besma Yacoubi-Loueslati
  • Wassim Y. Almawi
Original Article

Abstract

We investigated the association between six common and novel interleukin-6 (IL-6) polymorphisms with the risk of cervical cancer (CC) among Tunisians. Study subjects comprised 112 CC cases and 164 control women. Genotyping of IL-6 rs2069845, rs2069840, rs1474348, rs1800795, rs1800797, rs2069827 variants was done by real-time PCR, with defined clusters. The allelic and genotypic distributions of the tested IL-6 SNPs were comparable between CC patients and control women. Stratification according to FIGO staging revealed that rs1800795 homozygous major allele genotype (P = 0.033; OR =0.49(0.25–0.95)) and major allele (P = 0.037; OR = 0.57 (0.33–0.97)) were protective of CC. Moreover, carriage of rs1474348 major allele was also protective of CC (P = 0.014; OR = 0.53(0.32–0.88)), while higher rs1474348 minor allele frequency was seen in CC patients with early FIGO stage (P = 0.044; OR = 0.39 (0.15–1.00)), thus implicating rs1474348 in CC evolution and progression of angiogenesis. Haploview analysis demonstrated high linkage disequilibrium (LD) between rs2069845, rs2069840, rs1474348 and rs1800795, and 6-locus haplotype analysis identified GACCCA haplotype to be positively associated with increased CC, while GAGGGG haplotype was negatively associated with CC, thus suggesting a protective role for this haplotype in CC. Furthermore, there was a significant association between the incidence of CC and the use hormonal contraception (P = 0.047; OR = 1.97 (0.94–4.13)) and smoking (P < 0.001; OR = 7.12 (2.97–17.04)). The IL-6 variants rs1800795 and rs1474348, and haplotypes GACCCA and GAGGGG, along with use of hormonal contraceptives and smoking, are major risk factors of CC susceptibility and evolution among Tunisian women.

Keywords

Interleukin-6 Cervical cancer FIGO stages Polymorphisms Haplotypes Tunisians 

Notes

Acknowledgment

We thank all women with CC and control women who participated in the present study.

Compliance with Ethical Standards

Conflict of Interest

None of the authors have any conflict of interest to declare.

References

  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA: Cancer Journal for Clinicians 61:69–90Google Scholar
  3. 3.
    Bedoya AM, Jaramillo R, Baena A, Castano J, Olaya N, Zea AH et al (2012) Location and density of immune cells in precursor lesions and cervical cancer. Cancer Microenviron. doi: 10.1007/s12307-012-0097-8 PubMedPubMedCentralGoogle Scholar
  4. 4.
    Villa LL (2006) Biology of genital human papillomaviruses. International Journal of Gynecology and Obstetrics 94:3–7CrossRefGoogle Scholar
  5. 5.
    Rajeevan MS, Swan DC, Nisenbaum R, Lee DR, Vernon SD, Ruffin MT et al (2005) Epidemiologic and viral factors associated with cervical neoplasia in HPV-16-positive women. Int J Cancer 115:114–120CrossRefPubMedGoogle Scholar
  6. 6.
    Ribeiro KCB (2008) Cancer do colo do Utero: Epidemiologia do cancer do colo do utero – fatores demograficos e fatores de Risco. Tecmedd 18–23Google Scholar
  7. 7.
    Barton BE, Jackson JV (1993) Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model. Infect Immun 61:1496PubMedPubMedCentralGoogle Scholar
  8. 8.
    Eustace D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E (1993) Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol 50:15–19CrossRefPubMedGoogle Scholar
  9. 9.
    Tartour E, Gey A, Sastre-Garau X, Pannetier C, Mosseri V, Kourilsky P et al (1994) Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. Cancer Res 54:6243–6248PubMedGoogle Scholar
  10. 10.
    Castrilli G, Tatone D, Diodoro MG, Rosini S, Piantelli M, Musiani P (1997) Interleukin 1 alpha and interleukin 6 promote the in vitro growth of both normal and neoplastic human cervical epithelial cells. Br J Cancer 75:855–859CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Abdelwahab SI, Abdul AB, Zain ZN, Hadi AH (2012) Zerumbone inhibits interleukin-6 and induces apoptosis and cell cycle arrest in ovarian and cervical cancer cells. Int Immunopharmacol 12:594–602CrossRefPubMedGoogle Scholar
  12. 12.
    Zidi S, Stayoussef M, Gazouani E, Mezlini A, Yacoubi-Loueslati B, Almawi WY (2015) Relationship of common vascular endothelial growth factor polymorphisms and haplotypes with the risk of cervical cancer in Tunisians. Cytokine 74(1):108–112CrossRefPubMedGoogle Scholar
  13. 13.
    Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ (1996) Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271:736–741CrossRefPubMedGoogle Scholar
  14. 14.
    Wei L-H, Kuo M-L, Chen C-A, Cheng W-F, Cheng S-P, Hsieh F-J et al (2001) Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol 82:49–56CrossRefPubMedGoogle Scholar
  15. 15.
    Castro FA, Haimila K, Sareneva I, Schmitt M, Lorenzo J, Kunkel N et al (2009) Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population–a candidate gene approach. Int J Cancer 125:1851–1858CrossRefPubMedGoogle Scholar
  16. 16.
    Gangwar R, Mittal B, Mittal RD (2009) Association of interleukin-6 -174G/C promoter polymorphism with risk of cervical cancer. Int J Biol Markers 24:11–16CrossRefPubMedGoogle Scholar
  17. 17.
    Nogueira de Souza NC, Brenna SM, Campos F, Syrjanen KJ, Baracat EC, Silva ID (2006) Interleukin-6 polymorphisms and the risk of cervical cancer. Int J Gynecol Cancer 16:1278–1282CrossRefPubMedGoogle Scholar
  18. 18.
    Shi T-Y, Zhu M-L, He J, Wang M-Y, Li Q-X, Zhou X-Y et al (2013) Polymorphisms of the interleukin 6 gene contribute to cervical cancer susceptibility in eastern Chinese women. Hum Genet 132:301–312CrossRefPubMedGoogle Scholar
  19. 19.
    Srivani R, Nagarajan B (2003) A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer. Int J Gynecol Cancer 13:331–339CrossRefPubMedGoogle Scholar
  20. 20.
    Porto CRC, de Oliveira Kleine JPF, Longatto AF, da Silva IDCG (2014) Polymorphism of interleukin-6 is not associated with the presence or absence of high HPV E6/E7. Anticancer Res 34:3501–3504PubMedGoogle Scholar
  21. 21.
    Grimm C, Watrowski R, Baumühlner K, Natter C, Tong D, Wolf A et al (2011) Genetic variations of interleukin-1 and −6 genes and risk of cervical intraepithelial neoplasia. Gynecol Oncol 121:537–541CrossRefPubMedGoogle Scholar
  22. 22.
    Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valente PT e al. Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression—clinicopathological correlation. Gynecol Oncol 2007; 105: 157–165.Google Scholar
  23. 23.
    Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S et al (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Investig 102(7):1369CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Xu B, Niu X-B, Wang Z-D, Cheng W, Tong N, Mi Y-Y et al (2011) IL-6− 174G > C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controls. Mol Biol Rep 38(4):2589–2596CrossRefPubMedGoogle Scholar
  25. 25.
    Zhang H, Xu Y, Li L, Liu R, Ma B (2012) The interleukin-6 -174G/C polymorphism and prostate cancer risk: a systematic review and meta-analysis. Urol Int 88:447–453CrossRefPubMedGoogle Scholar
  26. 26.
    Upadhyay R, Jain M, Kumar S, Ghoshal UC, Mittal B (2008) Association of interleukin-6 (−174G > C) promoter polymorphism with risk of squamous cell esophageal cancer and tumor location: an exploratory study. Clincal Immunology 128:199–204CrossRefGoogle Scholar
  27. 27.
    Slattery ML, Curtin K, Sweeney C, Wolff RK, Baumgartner RN, Baumgartner KB et al (2008) Modifying effects of IL-6 polymorphisms on body size-associated breast cancer risk. Obesity 16:339–347CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Vairaktaris E, Yiannopoulos A, Vylliotis A, Yapijakis C, Derka S, Vassiliou S et al (2006) Strong association of interleukin-6 -174 G > C promoter polymorphism with increased risk of oral cancer. Int J Biol Markers 21:246–250CrossRefPubMedGoogle Scholar
  29. 29.
    Grimm C, Six L, Tomovski C, Baumühlner K, Natter C, Tong D et al (2005) A common interleukin-6 promoter polymorphism in patients with vulvar cancer. J Soc Gynecol Investig 12:617–620CrossRefPubMedGoogle Scholar
  30. 30.
    Beral PV, de González AB, Colin D, Franceschi S, Goodhill A, Green J, Peto J et al (2007) Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370(9599):1609–1621Google Scholar
  31. 31.
    Hea Young O (2016) Mi Kyung Kim, Sang-Soo Seo, Jae-Kwan Lee. Association of combined tobacco smoking and oral contraceptive use with cervical intraepithelial neoplasia 2 or 3 in Korean women. Journal of Epidemiology 26(1):22–29CrossRefGoogle Scholar
  32. 32.
    Nicol AF, Fernandes ATG, Grinsztejn B, Russomano F, Silva JRL, Tristão A et al (2005) Distribution of immune cell subsets and cytokine-producing cells in the uterine cervix of human papillomavirus (HPV)-infected women: influence of HIV-1 coinfection. Diagn Mol Pathol 14(1):39–47CrossRefPubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2016

Authors and Affiliations

  • Sabrina Zidi
    • 1
    Email author
  • Mouna Stayoussef
    • 1
  • Bano L. Alsaleh
    • 2
  • Ezzedine Gazouani
    • 3
  • Amel Mezlini
    • 4
  • Bashayer H. Ebrahim
    • 2
  • Besma Yacoubi-Loueslati
    • 1
  • Wassim Y. Almawi
    • 2
  1. 1.Department of Biology, Faculty of Sciences of Tunis, Laboratory of Mycology, Pathologies and Biomarkers: LR16ES05El Manar UniversityTunisTunisia
  2. 2.Department of Medical BiochemistryArabian Gulf UniversityManamaBahrain
  3. 3.Military Hospital of Tunis, Laboratory of ImmunologyTunisTunisia
  4. 4.Salah Azeiz Oncology InstituteTunisTunisia

Personalised recommendations